Use of Belimumab for Treating Systemic Lupus Erythematosus
The Belimumab treatment was placed under a managed access agreement (MAA) in 2016 making funding is available from NHS England for up to 300 patients. This applied until October 2020. In March 2019, only 113 or the proposed 300 patients had started treatment in England, which was lower than expected. Further details were given in the letter below:
Letter concerning the Belimumab MAA
This email was circulated to BAD members at the request of Dr Cate Orteu, Specialised Dermatology Clinical Reference Group Chair 2019.
The full NICE review on the use of Belimumab for treating Systemic Lupus Erythematosus is due for publication on the 25th November 2021.